Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease.
Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease.
复制标题
DOI：
10.3233/jad-2010-100012
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Carlsson CM
中科院分区：
文献类型：
--
作者：
Carlsson CM
The prevalence of Alzheimer’s disease (AD) is increasing rapidly, heightening the importance of finding effective preventive therapies for this devastating disease. Midlife vascular risk factors, including type 2 diabetes mellitus (T2DM), have been associated with increased risk of AD decades later and may serve as targets for AD prevention. Studies to date suggest that T2DM and hyperinsulinemia increase risk for AD, possibly through their effects on β-amyloid metabolism and cerebrovascular dysfunction - two early findings in preclinical AD pathology. This paper reviews the evidence supporting a relationship between T2DM, hyperinsulinemia, and diabetic dyslipidemia on the development of AD, discusses DM treatment trials and their preliminary results on cognitive function, and proposes some strategies for optimizing future AD prevention trial design.
